GenrAb discovers and develops naturally occurring, fully‑human neuroprotective antibodies using proprietary immunogenetic models applied to cerebrospinal fluid from patients with active neurological disease. Its lead candidate, TGM‑010, has repeatedly demonstrated the ability to cross the blood‑brain barrier, internalize into neurons, and engage stress‑management machinery to reduce neurological disability. The company says it is building a growing pipeline of partnerable neurotherapeutic antibodies selected for antineuronal capabilities and potential to manage neuronal stress. Proceeds from the announced financing will allow GenrAb to emerge from stealth and accelerate TGM‑010 through IND enabling work toward human clinical studies in 2026. GenrAb was founded on technology exclusively licensed from UT Southwestern Medical Center and is headquartered in BioLabs at Pegasus Park in Dallas. The company has received multiple regional awards recognizing its approach to treating neurodegeneration.

Total raised

$6M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2025